Atara Biotherapeutics Inc Market Cap ($35.19 Million)
Market Cap & Net Worth: Atara Biotherapeutics Inc (ATRA)
Atara Biotherapeutics Inc market cap. Atara Biotherapeutics Inc (NASDAQ:ATRA) has a market capitalization of $35.19 Million ($35.19 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22990 globally and #5043 in its home market, demonstrating a -1.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atara Biotherapeutics Inc's stock price $8.20 by its total outstanding shares 7210235 (7.21 Million). Also see Atara Biotherapeutics Inc (ATRA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Atara Biotherapeutics Inc Market Cap History (2015–2026)
Atara Biotherapeutics Inc market cap history from 2015 to 2026. Data shows change from $4.76 Billion to $59.12 Million (-33.54% CAGR). Check Atara Biotherapeutics Inc (ATRA) share price today for real-time trading data and today's change.
Index Memberships
Atara Biotherapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #650 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2155 of 3165 |
Weight: Atara Biotherapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Atara Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atara Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Atara Biotherapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.74x
Atara Biotherapeutics Inc's market cap is 0.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.54 Billion | $3.55 Million | -$306.62 Million | 996.18x | N/A |
| 2021 | $2.84 Billion | $20.34 Million | -$340.14 Million | 139.67x | N/A |
| 2022 | $591.24 Million | $63.57 Million | -$228.30 Million | 9.30x | N/A |
| 2023 | $92.44 Million | $8.57 Million | -$276.13 Million | 10.78x | N/A |
| 2024 | $95.97 Million | $128.94 Million | -$85.40 Million | 0.74x | N/A |
Competitor Companies of ATRA by Market Capitalization
Companies near Atara Biotherapeutics Inc in the global market cap rankings as of November 5, 2026. Also see ATRA asset base for a full breakdown of the balance sheet.
Key companies related to Atara Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Atara Biotherapeutics Inc (2015–2026)
Market capitalization of Atara Biotherapeutics Inc from 2015 to today. Between 2015 and today, Atara Biotherapeutics Inc's market cap moved from $4.76 Billion to $ 59.12 Million, with a yearly change of -33.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $59.12 Million | -54.67% |
| 2025 | $130.43 Million | +35.91% |
| 2024 | $95.97 Million | +3.82% |
| 2023 | $92.44 Million | -84.37% |
| 2022 | $591.24 Million | -79.19% |
| 2021 | $2.84 Billion | -19.71% |
| 2020 | $3.54 Billion | +19.19% |
| 2019 | $2.97 Billion | -52.59% |
| 2018 | $6.26 Billion | +91.93% |
| 2017 | $3.26 Billion | +27.46% |
| 2016 | $2.56 Billion | -46.23% |
| 2015 | $4.76 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Atara Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.19 Million USD |
| MoneyControl | $35.19 Million USD |
| MarketWatch | $35.19 Million USD |
| marketcap.company | $35.19 Million USD |
| Reuters | $35.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more